by Elena Iemma | Feb 13, 2026 | Uncategorized
Day 1 Afternoon Workshop: Streamlining Immunogenicity Assessment of Host Cell Proteins (HCPs): Insights and Case Studies Workshop leaders: Anne De Groot, EpiVax | Ben Gabriel, EpiVax | Marla Abodeely, Sanofi | Vibha Jawa, EpiVax Host cell...
by Elena Iemma | Jan 12, 2026 | Blog, News
In 2025, EpiVax advanced the science of immunogenicity assessment through AI-driven ADA prediction, enhanced in silico tools, expanded in vitro assays and consulting offerings, and new regulatory frameworks supporting biologics and generic peptides. Advancing...
by Elena Iemma | Dec 23, 2025 | Blog
EpiVax Supports Life-Saving Programs Through Partnerships with GAIA Vaccine Foundation and Clínica Esperanza/Hope Clinic At EpiVax, we believe in the power of science to improve human health, but we also recognize that science alone cannot reach every community. That...
by Elena Iemma | Dec 8, 2025 | News
EpiVax and FDA Scientists Publish New Insights on Immunogenicity Risks of Peptide-Related Impurities in Generic Teriparatide PROVIDENCE, R.I., Dec. 8, 2025 — EpiVax, Inc., with U.S. Food and Drug Administration (FDA) and CUBRC, Inc. (Buffalo, NY) scientist...
by Elena Iemma | Dec 1, 2025 | Blog
Doing Well and Giving Back in December On Being Human Humans share 96-98% of our DNA with non-human primates. And yet, for many years, we have caged our “NHP” brothers and sisters and used them to validate our scientific hypotheses. Finally,...
